BridgeMD
New treatment option for COPD
Official title Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation
ClinicalTrials.gov ID: NCT06331416
What this study is testing
- What it's testing
- Chronic obstructive pulmonary disease (COPD) exacerbations are risk factors for disease progression and short-term re- hospitalizations. We propose a randomized controlled trial to evaluate the efficacy of a one-device multiparameter telemonitoring in reducing functional decline, symptoms, and risk of re-hospitalization of patients discharged after hospitalization for exacerbated COPD.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Able to understand and sign the informed consent form.
- Already established diagnosis of COPD according to Global Initiative for Obstructive Lung Disease (GOLD) guidelines.[13]
- Diagnosis of COPD exacerbation at admission, according to GOLD guidelines.[13]
- Arterial partial pressure of oxygen (PaO2) \ 60 mmHg in ambient air at rest at discharge, if not on long-term oxygen therapy on ventilation.
- Arterial partial pressure of oxygen (PaO2) \ 60 mmHg on oxygen supplement at discharge, if already on long-term oxygen therapy on ventilation. g) Age...
You likely can't join if
- Heart failure as the main cause of acute respiratory failure
- Acute pulmonary embolism/chronic pulmonary thromboembolism
- Interstitial lung disease as the main cause of acute respiratory failure
- Pneumonia as the main cause of acute respiratory failure
- Chronic renal failure with dialysis dependence
- Immunosuppression (i.e. cancer on treatment, post-organ transplantation, HIV-positive, on immunosuppressant therapy)
See the full eligibility criteria
- Able to understand and sign the informed consent form.
- Already established diagnosis of COPD according to Global Initiative for Obstructive Lung Disease (GOLD) guidelines.[13]
- Diagnosis of COPD exacerbation at admission, according to GOLD guidelines.[13]
- Arterial partial pressure of oxygen (PaO2) \ 60 mmHg in ambient air at rest at discharge, if not on long-term oxygen therapy on ventilation.
- Arterial partial pressure of oxygen (PaO2) \ 60 mmHg on oxygen supplement at discharge, if already on long-term oxygen therapy on ventilation. g) Age \ = 18 years old at randomization.
- Heart failure as the main cause of acute respiratory failure
- Acute pulmonary embolism/chronic pulmonary thromboembolism
- Interstitial lung disease as the main cause of acute respiratory failure
- Pneumonia as the main cause of acute respiratory failure
- Chronic renal failure with dialysis dependence
- Immunosuppression (i.e. cancer on treatment, post-organ transplantation, HIV-positive, on immunosuppressant therapy)
- Progressive neuro-muscular disorders
- Cognitively impaired, dementia or decompensated psychiatric disorder
- Quadriplegia/Hemiplegia or quadriparesis/hemiparesis
- Do-not-resuscitate order
- Any other condition that in the opinion of the investigator may significantly impact with patient's capability to comply with the protocol
The study team makes the final eligibility decision.
Where it's taking place
- Trieste, Italy
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Trieste, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.